Gender-related imaging issues in assessment of coronary artery disease by nuclear techniques.
Heart disease is a major threat to women's health. However, noninvasive evaluation of women for the presence of significant heart disease is often problematic. Cardiovascular nuclear tests interrogate different consequences of physiologically significant coronary artery disease (CAD). Myocardial perfusion imaging supplies information about regional myocardial blood flow. Radionuclide angiocardiography provides information about ejection fraction and regional wall motion. Infarct and metabolic imaging yield information about myocardial viability. This article briefly discusses the concepts and radionuclides involved in cardiovascular nuclear testing and reviews published studies as they relate to assessment of coronary artery disease in women. Myocardial perfusion imaging is a reasonable test for detection of coronary artery disease in women, especially when attenuation artifacts from breast tissue are taken into account. Intravenous dipyridamole stress provides comparable overall accuracy in women and men although women reportedly have a higher incidence of side effects; gender-specific data have not been reported for adenosine. Sufficient gender-specific data are also not currently available for either 99mTc or positron-emitting perfusion tracers. Exercise radionuclide angiography can help determine the probability of significant left main or severe three vessel disease but provides only limited prognostic information in women with CAD. Thus in women, although choice of testing using nuclear techniques depends in part on local experience and expertise, myocardial perfusion imaging appears preferable to radionuclide angiocardiography for detection of significant CAD. To determine the most accurate methods to evaluate women for the presence of significant CAD, all current and future studies of diagnostic testing for CAD should analyze data separately for women and men.
Grover-McKay
M
M
Division of Cardiovascular Diseases, University of Iowa, Iowa City 52242-1081, USA.
D003327:Coronary Disease / Q000000981:diagnostic imaging* / Q000453:epidemiology*; D004176:Dipyridamole; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D011379:Prognosis; D011875:Radionuclide Angiography / Q000706:statistics & numerical data; D012016:Reference Values; D012727:Sex Characteristics; D012737:Sex Factors; D013667:Technetium; D017256:Technetium Tc 99m Sestamibi; D013794:Thallium Radioisotopes; D014055:Tomography, Emission-Computed / Q000706:statistics & numerical data; D015899:Tomography, Emission-Computed, Single-Photon / Q000706:statistics & numerical data; D014665:Vasodilator Agents
D013794:Thallium Radioisotopes; D014665:Vasodilator Agents; D004176:Dipyridamole; D013667:Technetium; D017256:Technetium Tc 99m Sestamibi